Should a 7‑year‑old child scheduled for a Crysvita (burosumab) infusion proceed with the infusion despite having fever, cough, congestion, and headache with an unknown current temperature?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Defer the Crysvita Infusion Until Fever Status is Clarified and Symptoms Resolve

The infusion center should NOT proceed with the Crysvita infusion today until the child's current temperature is measured and the acute illness is evaluated. If fever is present or the child appears acutely ill, the infusion should be postponed until symptoms resolve.

Clinical Reasoning

Why Temperature Assessment is Critical

The parent reports fever as one of the symptoms, but the current fever status is unknown. This is a critical gap that must be addressed before proceeding:

  • Pyrexia (fever) is the most common adverse event with Crysvita, occurring in approximately 75% of pediatric patients in clinical trials 1, 2
  • Administering Crysvita during an active febrile illness could:
    • Mask or confound the source of fever (drug-related vs. infection-related)
    • Potentially worsen the child's clinical status
    • Make it impossible to distinguish between treatment-emergent adverse events and progression of the underlying illness

Safety Profile Considerations

While Crysvita has a generally favorable safety profile 1, 3:

  • Most treatment-emergent adverse events are mild to moderate 3, 4
  • The drug is well-tolerated with rare serious adverse events 2, 5
  • However, cough is also a common adverse reaction (>25% in pediatric patients) 1

The overlap between the child's current symptoms (fever, cough, headache) and known Crysvita adverse events creates a clinical dilemma that makes it unsafe to proceed without first establishing baseline status.

Recommended Action Algorithm

Step 1: Immediate Assessment (Before Infusion Decision)

  • Measure temperature now at the infusion center
  • Perform brief clinical assessment for:
    • Respiratory distress (increased respiratory rate, retractions, grunting)
    • Hydration status
    • Level of alertness/activity
    • Severity of cough and congestion

Step 2: Decision Tree Based on Findings

If temperature ≥38.5°C (101.3°F) OR child appears acutely ill:

  • DEFER the infusion
  • Advise parent to seek medical evaluation for the acute illness
  • Reschedule infusion for after symptom resolution (typically 24-48 hours after fever resolves without antipyretics)

If temperature <38.5°C AND child appears well (mild URI symptoms only):

  • Consider proceeding with infusion
  • Ensure close monitoring during and after infusion
  • Document baseline symptoms clearly to distinguish from potential treatment-emergent adverse events
  • Provide clear return precautions to parents

If unable to assess temperature or clinical status adequately:

  • DEFER the infusion (err on the side of caution)

Key Pitfalls to Avoid

  1. Never proceed with an infusion when fever status is unknown - this creates an unsafe situation where you cannot properly monitor for adverse events

  2. Do not assume "just a cold" is benign - while the symptoms may represent a simple viral URI, children with chronic conditions receiving biologic therapy warrant more conservative management

  3. Document everything - if you do proceed after assessment, clearly document the child's baseline symptoms, vital signs, and clinical appearance to enable proper adverse event monitoring

  4. Consider the 2-week dosing interval - Crysvita is given every 2 weeks 1, 3. A delay of 2-3 days for illness resolution will not significantly impact therapeutic efficacy and is far safer than proceeding with an infusion during acute illness

Practical Guidance

The infusion center should:

  • Take the child's temperature immediately
  • If fever is present or child appears ill: reschedule for 24-48 hours after symptom resolution
  • If afebrile and well-appearing with only mild symptoms: use clinical judgment but lean toward deferral given unknown fever history
  • Contact the prescribing physician if there are questions about proceeding

The risk-benefit analysis strongly favors deferral when acute illness is present or suspected, as the consequences of administering Crysvita during active infection (diagnostic confusion, potential worsening of symptoms) outweigh the minimal delay in therapy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.